Trial Profile
A Phase II Trial of TAS-102 (Lonsurf) in Patients With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma After Progression Through First Line Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2021
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 04 Aug 2020 Status changed from active, no longer recruiting to discontinued.
- 20 Feb 2020 Status changed from suspended to active, no longer recruiting.
- 16 Aug 2019 Planned End Date changed from 1 Nov 2020 to 1 Nov 2021.